A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody–drug conjugate, in relapsed/refractory B-cell non-Hodgkin …

BS Kahl, M Hamadani, J Radford, C Carlo-Stella… - Clinical Cancer …, 2019 - AACR
Abstract Purpose: ADCT-402 (loncastuximab tesirine) is an antibody–drug conjugate
comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human …
被引用次数：93 相关文章

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non …

BS Kahl, M Hamadani, J Radford… - … : an official journal …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose ADCT-402 (loncastuximab tesirine) is an antibody-drug conjugate comprising a
CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study …

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non …

BS Kahl, M Hamadani, J Radford… - Clinical Cancer …, 2019 - research.manchester.ac.uk
Purpose: ADCT-402 (loncastuximab tesirine) is an antibody–drug conjugate comprising a
CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study …

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non …

BS Kahl, M Hamadani, J Radford… - … Cancer Research: an …, 2019 - europepmc.org
Purpose ADCT-402 (loncastuximab tesirine) is an antibody-drug conjugate comprising a
CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study …

[引用][C] A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non …

B Kahl, M Hamadani, J Radford… - CLINICAL CANCER …, 2019 - iris.hunimed.eu
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based
Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma IRIS …

A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody–drug conjugate, in relapsed/refractory B-cell non-Hodgkin …

BS Kahl, M Hamadani, J Radford… - Clinical Cancer …, 2019 - profiles.wustl.edu
Purpose: ADCT-402 (loncastuximab tesirine) is an antibody–drug conjugate comprising a
CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study …

A phase I study of ADCT-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed/refractory B-cell Non-Hodgkin …

BS Kahl, M Hamadani, JA Radford, C Carlo-Stella… - 2019 - christie.openrepository.com
PURPOSE: ADCT-402 (loncastuximab tesirine) is an antibody-drug conjugate comprising a
CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study …